retatrutide phase 2 nejm 2023 weight loss percent 48 weeks Retatrutide (not yet approved in US but people using anyway) promises even potentially greater weight loss amongst the GLP1 drugs. https://www.nejm .org/doi/full/10.1056/NEJMoa2301972 Dr. Alex Tatem on Retatrutide:
Description
The inflammation-cardiovascular connection deserves deeper exploration
GLP-1 activity suppresses hunger and increases feelings of fullness after meals
VettaFi LLC (VettaFi) is the index provider for THNR, for which it receives an index licensing fee
A reduction in TH2-related cytokines was also observed after GE2 treatment in females ( p = 0.005
Medical weight loss touches several areas that a primary care practice is already built to manage
